AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023| Amgen
Amgen presented new research on Otezla (apremilast) for psoriatic arthritis at EULAR 2023. The MOSAIC study used MRI to show inflammation reduction, with greater effects in moderate disease. Exploratory analysis found Otezla improved cardiometabolic parameters. Findings were presented June 2-3.
How this was made
The 30-second read
Why it matters
The study provides new efficacy evidence that could support expanded use or future indications, potentially influencing sales and pipeline valuation.
Market read
First public disclosure of Phase 4 MRI results may modestly affect Amgen's stock and peers in the rheumatology space.
What to watch
Safety profile (diarrhea, nausea) and modest structural impact could temper enthusiasm.
Background
Amgen's Otezla is an oral PDE4 inhibitor approved for psoriasis and psoriatic arthritis; the MOSAIC study is the first to use MRI for inflammation assessment.
Ticker impact
Amgen presented new Phase 4 MOSAIC study results on Otezla for psoriatic arthritis at EULAR 2023, showing MRI‑measured inflammation reduction.
potential modest upside as market prices in improved efficacy data
First disclosure of Phase 4 MRI outcomes; efficacy signals are new and material for a marketed drug.
Market effects
May reinforce confidence in biotech companies developing oral small‑molecule therapies for inflammatory diseases.
Limited to US biotech and pharma investors; no broader regional effect.
Modest, as data pertains to a specific drug rather than a macro trend.
Counterpoint
If the MRI improvements do not translate to long‑term clinical outcomes, the data may be over‑hyped.
Key entities
- CompanyAmgen
US‑based biopharma presenting new Otezla data.
- DrugOtezla (apremilast)
Oral therapy for psoriatic arthritis evaluated in the MOSAIC study.